Invokana Dosage/Direction for Use

Dosage: Adults 18 years of age and older: The recommended dose of INVOKANA is 100 mg or 300 mg once daily. The 300 mg dose may be considered for patients with an eGFR ≥60mL/min/1.73 m2 (CrCl ≥ 60 mL/min), who need tighter glycemic control and who have a low risk of adverse reactions associated with reduced intravascular volume with INVOKANA treatment.
A starting dose of 100 mg once daily should be used in patients on loop diuretics and elderly people (aged 75 and over). In patients with evidence of reduced intravascular volume, correcting this condition prior to initiation of INVOKANA is recommended. For those patients who are tolerating INVOKANA 100 mg and who need tighter glycemic control, the dose can be increased to INVOKANA 300 mg.
When INVOKANA is used as add-on therapy with insulin or an insulin secretagogue (e.g., sulfonylurea), a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia.
Administration: INVOKANA should be taken orally once a day, preferably before the first meal of the day. Tablets are to be swallowed whole.
Missed dose: If a dose is missed, it should be taken as soon as the patient remembers; however, a double dose should not be taken on the same day.
Special populations: Pediatrics (< 18 years of age): The safety and efficacy of INVOKANA have not been established in pediatric patients.
Elderly: In patients ≥75 years of age, the starting dose of INVOKANA is 100 mg once daily. Renal function and risk of volume depletion should be taken into account (see Warnings, Precautions and Adverse Reactions).
Renal impairment: In patients with an estimated glomerular filtration rate (eGFR) 45 to < 60 mL/min/1.73 m2 [CrCl 45 to < 60 mL/min], the dose of INVOKANA is limited to 100 mg once daily. INVOKANA should not be initiated in patients with an eGFR < 45 mL/min/1.73 m2 [CrCl < 45 mL/min]. INVOKANA should be discontinued when eGFR is persistently < 45 mL/min/1.73 m2 [CrCl< 45 mL/min] (see Warnings, Precautions and Adverse Reactions).
INVOKANA should not be used in patients with an eGFR < 45 mL/min/1.73 m2 [CrCl < 45 mL/min] as it would not be effective in these patient populations (see Precautions).